Author(s):
Serambeque, Beatriz ; Mestre, Catarina ; Barros, Gabriela ; Marques Teixo, Ricardo Jorge ; Marto, Carlos Miguel ; Gonçalves, Ana Cristina ; Caramelo, Francisco ; Silva, Isabel ; Paiva, Artur ; Beck, Hans C. ; AS, Carvalho ; Botelho, MF ; Carvalho, Maria João ; Matthiesen, Rune ; Laranjo, Mafalda
Date: 2024
Persistent ID: http://hdl.handle.net/10362/168824
Origin: Repositório Institucional da UNL
Subject(s): aldehyde dehydrogenase; ALDH inhibition; cancer stem cells; endometrial neoplasms; N,N-diethylaminobenzaldehyde; proteomics; stemness; Oncology; Cancer Research; SDG 3 - Good Health and Well-being
Description
Publisher Copyright: © 2024 by the authors.
Endometrial cancer is one of the most common gynaecological malignancies. Although often diagnosed at an early stage, there is a subset of patients with recurrent and metastatic disease for whom current treatments are not effective. Cancer stem cells (CSCs) play a pivotal role in triggering tumorigenesis, disease progression, recurrence, and metastasis, as high aldehyde dehydrogenase (ALDH) activity is associated with invasiveness and chemotherapy resistance. Therefore, this study aimed to evaluate the effects of ALDH inhibition in endometrial CSCs. ECC-1 and RL95-2 cells were submitted to a sphere-forming protocol to obtain endometrial CSCs. ALDH inhibition was evaluated through ALDH activity and expression, sphere-forming capacity, self-renewal, projection area, and CD133, CD44, CD24, and P53 expression. A mass spectrometry-based proteomic study was performed to determine the proteomic profile of endometrial cancer cells upon N,N-diethylaminobenzaldehyde (DEAB). DEAB reduced ALDH activity and expression, along with a significant decrease in sphere-forming capacity and projection area, with increased CD133 expression. Additionally, DEAB modulated P53 expression. Endometrial cancer cells display a distinct proteomic profile upon DEAB, sharing 75 up-regulated and 30 down-regulated proteins. In conclusion, DEAB inhibits ALDH activity and expression, influencing endometrial CSC phenotype. Furthermore, ALDH18A1, SdhA, and UBAP2L should be explored as novel molecular targets for endometrial cancer.
